▶주메뉴 바로가기
▶본문 바로가기
Samsung BioLogics has won a lawsuit against Switzerland-based Lonza to nullify its patents involving its cell line development technology in South Korea, according to sources Oct. 1. The court noted Lonza’s patented technology is not new compared to the one that is being widely used and it is als...
South Korean biotech firm Genexine announced on Sept. 27 that it has signed a contract with the Thai company KinGen Holdings to establish a 50:50 joint venture named KinGen Biotech. KinGen Holdings is a Thai consortium that is backed by the government, schools and divers investors, according to Ge...
Celltrion Healthcare on Sept. 27 announced its decision to expand sales in the Middle East. He company has got approval to exclusively supply Remsima, its version of Johnson & Johnson’s Remicade from the third quarter this year. According to the company, its successful bid was due to its aggress...
Celltrion Group on Sept. 20 announced that European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended giving sales approval for Remsima SC. CHMP is responsible for preparing the opinions to EMA on questions concerning human medicines based on scientific evidence. ...
Medytox has participated in the seed-funding round of US startup LifeSprout, according to industry sources on Sept. 16. Although the Korean company declined to confirm the specific amount that it has funded, a local news outlet reported that it invested around $1.5 million in this round. The US c...
Korean pharmaceutical companies are making inroads into the Central and South American markets, betting on their steady growth. Samsung Bioepis, Celltrion Healthcare, Boryung Pharmaceutical, CJ HealthCare and Hanmi Pharmaceutical all announced in the first half of 2019 that they would begin or exp...
South Korean biopharmaceutical firm Celltrion announced Sept. 10 that its breast cancer biosimilar has been approved for sales in Canada. The regulatory body Health Canada has approved the data from nonclinical and clinical trials, and announced that Herzuma’s safety and effectiveness are compara...
South Korea’s Supreme Court has approved a grace period for Samsung BioLogics to defer the implementation of penalties imposed by the financial authorities by up to 30 days, the biopharma firm said in a regulatory filing on Sept. 10. As a result, sanctions on Samsung’s biopharma arm by Korea’...
Celltrion Group expects to receive approval for biosimilar Remsima SC from European authorities for sales before the end of this year, founder and Chairman Seo Jung-jin said at a bio conference on Aug. 28. “On Aug. 20, we answered the European Medicines Agency’s questions related to Remsima SC,...
South Korea’s Boryung Pharmaceutical announced on Aug. 27 it had received approval from the US Food and Drug Administration to start a phase 1 clinical trial of its drug candidate BR2002 The phase 1 clinical trial will be conducted among 90 patients who suffer non-Hodgkin’s lymphoma, a type of c...
The Korea Exchange, South Korea’s stock market operator, on Aug. 26 announced its decision to delist troubled Kolon Group ’s US gene therapy-developing unit Kolon TissueGene . In late March, a component of Kolon TissueGene’s gene therapy drug Invossa -- labeled as “a gene-containing chondr...
Celltrion in May established Celltrion Biopharma, its first unit in Ireland, for further expansion in the European biosimilar market, according to industry sources on Aug. 20. At the new unit, the Korean company plans to mainly conduct clinical trials to prove the safety of its biosimilars to loc...
South Korean bio company OliPass has decided to inject 1.2 billion won ($988,000) to establish a unit in the US, according to industry sources on Aug 12. The company hopes to further strengthen its partnership with US companies and apply for clinical trials after establishing the new unit. Accord...
Korean pharmaceutical company Yuhan announced on Aug. 7 that it has established new unit in Australia to expand its presence further globally. “We established Yuhan ANZ in Australia to focus more on open innovation for discovering new drug candidates and technologies,” the company said in a stat...
SillaJen shares bottomed out on Aug. 2 on news that the global phase 3 clinical trials of its signature liver cancer treatment Pexa-Vec are likely to be suspended. The biotech firm trading on South Korea’s tech-heavy bourse Kosdaq, took a 30 percent loss. As a result, the market cap fell to 2.2 ...
Posco threads new life to old uniforms for Philippine communities
NCSoft releases sustainability report to meet global green standards
Samsung may supply advanced image sensors for Apple: analyst
Hana chief cleared of severe punishment in DLF crisis
NCSoft launches official Discord channel for Throne and Liberty
Qoo10 liquidity crisis sparks massive complaints, fears of wider damage